Updated November 16, 2026: This article now includes comments from Robert Likić, a professor in the Unit of Clinical Pharmacology at University Hospital Centre Zagreb, on the move from the Phase 2b regimen to the planned pivotal design, and the six-month retreatment figures from Phase 2b’s open-label extension. Its analysis is otherwise unchanged.
In August, GH Research said its pivotal program for GH001, an inhaled form of the psychedelic mebufotenin (5-MeO-DMT) for treatment-resistant depression, was “intended to replicate the Phase 2b trial,” and that it continued to target a start in 2026. Its third-quarter report on November 13 contains neither statement. The company now expects an End-of-Phase 2 meeting with the FDA in the first quarter of 2027 and plans to start the pivotal program “shortly thereafter, subject to final alignment.”
The regimen they will test has also changed. GH001’s headline result, a 15.5-point improvement over placebo on the 0-to-60 Montgomery-Åsberg Depression Rating Scale (MADRS) at Day 8, came from patients who inhaled up to three escalating doses through a commercial vaporizer in a single sitting. The proposed pivotal design gives one fixed dose per visit through GH Research’s own device, with patients randomized to placebo or to one of at least two fixed dose levels, and reads the primary endpoint at Week 4.
The molecule carries over. The device, the dosing method and the timepoint that decides the trial do not.
The timing moved in steps. In March the company targeted initiation in 2026, in May “late 2026,” in August “in 2026.” The only FDA input on the design that the November release describes is “positive initial feedback,” and the company’s investor presentation labels the design “proposed” and “to be finalized” at the End-of-Phase 2 meeting. The written FDA responses GH Research received in July addressed its manufacturing and device plans, which the company says “appear Phase 3 ready”; the company has not described them as covering the trial design. The design work also follows a long pause in the United States: the FDA placed GH001’s investigational new drug application on clinical hold in September 2023 and lifted the hold in December 2025, and all of the company’s completed patient trials were run in Europe.
What carries over from Phase 2b, and what does not
| Phase 2b (GH001-TRD-201) | Planned pivotal | |
|---|---|---|
| Device | Volcano Medic vaporizer | GH Research’s Aerosol Delivery System |
| Dosing | Up to 3 inhalations (6, 12, 18 mg), an hour apart; the next only if no peak experience | One fixed dose per visit; parallel fixed-dose arms vs placebo; doses undisclosed |
| Blinded period | 7 days, one dosing day | 12 weeks, with re-treatment |
| Primary endpoint | MADRS change, Day 8 | MADRS change, Week 4 |
| Evidence for the regimen | 81 patients, randomized, placebo-controlled | 8 healthy volunteers, open-label |
Phase 2b from GH Research’s 2025 annual report and November 2026 investor presentation. Pivotal design as proposed on November 13, to be finalized with FDA.
The device switch is not new: GH Research has said since at least March that the pivotal program would use its own device, and it ran a healthy-volunteer study, GH001-HV-106, to bridge from the vaporizer. The new element is the dosing. Phase 2b’s escalation was guided by “peak experience,” a measure of psychedelic intensity the company devised, and as recently as its March annual report GH Research described an individualized dosing regimen in its pivotal program, listing as a risk that regulators might not accept peak experience to guide it.
The case for one dose
GH Research’s argument is about the device. In bench tests, the new system delivered 82 to 89 percent of the loaded dose, against 55 to 79 percent for the vaporizer; that is the dose leaving the device, not the amount reaching the bloodstream. On the old device, the company says, a single fixed dose produced a peak experience (a Peak Experience Scale score of at least 75) in 33 of 74 people pooled across four trials of healthy volunteers and patients at several doses, which is why Phase 2b titrated: after the third step, 70 of 81 patients had reached one in their first active treatment, counting the placebo group’s first open-label dose. The company itself describes these cross-trial figures as descriptive, not head-to-head. In HV-106, 7 of 8 healthy volunteers reached a peak experience after one inhalation of a dose GH Research plans to take into the pivotal program, which its presentation calls the mid dose. The company has not disclosed the dose levels or how many arms the trials will have.
That bridge has four limits:
- It is eight people. A 7-of-8 result is consistent with a true rate anywhere from about 47 to nearly 100 percent (95 percent interval, Behavioral Wire calculation).
- They were healthy volunteers, in an open-label study. No patient with depression has received GH001 through the new device in any trial GH Research has disclosed: both studies of the device, HV-106 and a 13-person U.S. study, enrolled healthy volunteers, and every patient trial used the vaporizer. The only single-dose patient data come from the old device: eight patients, four at each of two doses, in an open-label Phase 1/2 trial. No efficacy data exist for the planned regimen.
- The yardstick is the company’s own. GH Research’s annual report says it believes peak experience may correlate with clinical outcomes, but that it is subjective and its psychometric validation has not been completed.
- The exposure data are not public. A device switch is usually bridged on blood levels. HV-106 included a direct comparison of the two devices, and GH Research has not released its blood-level results.
The registry record for HV-106 also shows that the sponsor stopped the study after its single-dose and device-comparison parts, saying it had enough data to select doses. A planned part giving the three-step regimen through the new device was not run.
Robert Likić, a professor in the Unit of Clinical Pharmacology at University Hospital Centre Zagreb and lead author of a November 4 CNS Drugs review of mebufotenin’s clinical pharmacology, said the Phase 2b findings provide “a compelling rationale for further development,” but that the size of the 15.5-point effect “cannot automatically be extrapolated to the new regimen.” The device reportedly delivers the aerosol more consistently, he said, which is encouraging, but “improved delivery consistency does not necessarily establish equivalent systemic exposure, pharmacodynamic effects or clinical efficacy.” A fixed dose also removes the chance to adjust treatment to an individual’s response. He said pharmacokinetic and pharmacodynamic bridging, together with confirmation of safety and efficacy in patients, will be important.
Likić called the 7-of-8 result encouraging but said its predictive value for antidepressant efficacy “remains uncertain.” He added that “a subjective peak psychedelic experience is not an established surrogate endpoint for clinical improvement in depression,” that it has not been shown that any particular intensity of experience is necessary or sufficient for mebufotenin’s antidepressant effects, and that patients with treatment-resistant depression may differ from healthy volunteers in pharmacodynamic sensitivity, concomitant medication exposure and underlying neurobiology. The result, he said, supports the feasibility of the dosing strategy but cannot establish its therapeutic adequacy in the intended patients.
“I would consider the new approach scientifically reasonable, but not yet clinically validated.”
— Robert Likić, MD, PhD, FBPhS, Professor, Unit of Clinical Pharmacology, University Hospital Centre Zagreb
None of this shows the new regimen will work less well. A fixed dose removes the titration rule the company itself flagged as a regulatory risk, standardizes the dose leaving the device and, the company expects, fixes the visit at about an hour.
Week 4 tests something Phase 2b did not
Phase 2b, GH001’s only randomized, placebo-controlled trial in patients, compared drug and placebo for seven days. Patients had one dosing day, the primary endpoint was read at Day 8, and everyone then moved to open-label treatment. The six-month figures GH Research cites, 73 percent of the 63 completers in remission after an average of four treatments, have no placebo comparison.
The Phase 2b paper in JAMA Psychiatry also follows the 23 patients who were in remission at Day 8 on GH001 through the six-month open-label extension. Three stayed in remission with no further treatment, and 20 met retreatment criteria, with time to first retreatment of 6 weeks (range 2 to 12); 20 of the 23 were in remission at six months. Likić said those observations suggest sustained benefit is possible, but “do not establish how long remission persists after a single administration without further treatment.” He called the move to Week 4 “a meaningful change in the clinical question being addressed”: Phase 2b showed a strong early efficacy signal, and a Week 4 endpoint puts more weight on whether benefit persists. He regards the later endpoint as “clinically appropriate and potentially more informative, although it may prove more challenging to reproduce the original effect size.”
The proposed pivotal design keeps patients blinded for 12 weeks and, in GH Research’s presentation, includes re-treatment both before and after the Week 4 endpoint. The company has not disclosed the criteria for re-treatment or how many visits can fall before Week 4, so the primary result may reflect more than one dose for some patients. Either way, it would be the first placebo-controlled measure of GH001 beyond the first week, and blinding has to hold for longer: an intense psychedelic effect is a contrast with placebo that patients may recognize. The presentation lists outcome raters blinded to treatment; it does not say how the company will assess whether patients can tell which arm they are in. Likić said the drug’s “conspicuous psychoactive effects” make “preservation of treatment blinding particularly challenging,” and that prospective assessment of blinding integrity and treatment expectancy will be important in interpreting pivotal efficacy results. GH Research presents the design as consistent with FDA’s July 2026 final guidance on psychedelic trials, by its own summary of that non-binding document. It has not said whether Day 8 will remain a secondary endpoint.
BPL-003 is already on this design
The revised plan now resembles the one for BPL-003, an intranasal form of mebufotenin that Eli Lilly acquired with AtaiBeckley in September: fixed doses against placebo, a primary MADRS endpoint at Week 4 and a 12-week blinded core. BPL-003 reached that design earlier. AtaiBeckley reported in March 2026 that the FDA had indicated support for advancing to Phase 3, guiding topline data for early 2029, and in August that Phase 3 activities had been initiated. Neither of its two pivotal trials appeared on ClinicalTrials.gov when searched on November 13. GH001’s End-of-Phase 2 meeting is expected in the first quarter of 2027, roughly a year after AtaiBeckley reported the FDA’s support for BPL-003’s Phase 3, and GH Research has given no topline timing for its pivotal trials. The move into 2027 leaves BPL-003 further ahead on the pivotal-development timeline.
Capital does not appear to be the constraint. GH Research held $350.6 million in cash, cash equivalents and marketable securities on September 30, up from $280.7 million at the end of 2025, after an April share offering that raised $111.2 million net. It lost $46.6 million in the first nine months of the year. The company has not explained the timing change beyond the planned FDA meeting.
The same translation question extends to its second indication. GH Research plans a postpartum depression pivotal program, targeted for the second half of 2027, also with one fixed dose on the new device. Its basis is a 10-patient open-label trial that used one to three inhalations on the old one.
“Overall, I consider GH001 a promising investigational treatment with a strong preliminary efficacy signal.”
— Robert Likić, Professor, Unit of Clinical Pharmacology, University Hospital Centre Zagreb
Phase 2b established that mebufotenin, titrated to a strong psychedelic effect, separated from placebo by 15.5 MADRS points a week after one dosing day. The pivotal program will test whether one fixed dose per visit on a different device, with re-treatment allowed over 12 weeks, separates from placebo at Week 4. That is a related question, not the same one.